SNPMiner Trials by Shray Alag

SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT03349983

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)

An open-label Phase 1 trial to evaluate the safety and tolerability of MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines modified to express brachyury and T-cell costimulatory molecules in patients with a metastatic or unresectable locally advanced malignant solid tumor. Subjects will be given the following subcutaneous doses: two prime doses with MVA-BN-Brachyury and monthly boost doses with FPV-Brachyury for 6 months. The study will last approximately 104 weeks before starting long term follow up (FU).

NCT03349983 Safety Issues

1 Interventions

Name: MVA-BN-Brachyury/ FPV-Brachyury

Description: Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months

Type: Biological

MVA-BN-Brachyury/ FPV-Brachyury

Primary Outcomes

Description: Fraction of patients who experience a (Dose Limiting Toxicity) DLT.

Measure: Patients with Dose Limiting Toxicity

Time: up to 8 weeks

Purpose: Treatment

Sequential Assignment

There is one SNP


1 T790M

Patients with T790M mutations may continue receiving osimertinib while receiving vaccine. --- T790M ---

HPO Nodes